Oral Thin Films Market to Outdo Estimation of 8.7% CAGR by 2032: Fact.MR

The oral thin films market is anticipated to grow at a CAGR of 8.7% from 2022 to 2032, rising from a market value of US$ 3.12 billion to US$ 7.19 billion. By 2032, the U.S. is anticipated to hold a greater than 25% market share for oral thin films (OTF).
The Oral Thin Films industry report includes the CAGR figures and its variations for the specific predicted period.

The research offers a top-to-bottom analysis and evaluation of several market-related factors to aid in better decision-making. This industry study research offers in-depth explanations of market trends, market segmentation, competition analysis, and important advancements in the ABC sector.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=5776?AS

Major Stakeholders

• ZIM Laboratories Ltd.
• Indivior Plc.
• Aquestive Therapeutics Inc.
• LIVKON Pharmaceuticals Pvt. Ltd.
• Sunovion Pharmaceuticals Inc.
• NAL Pharma
• CURE Pharmaceutical
• IntelGenx Corp.
• Kyu Pharmaceutical Co. Ltd.
• C.L. Pharm

Key Statistics Supporting the Surge

• The global oral thin films market is set to expand at a CAGR of 8.7% and reach US$ 7,187.1 million by the end of 2032.
• The market evolved at 6.1% CAGR between 2017 and 2021.
• Under product vertical, the orodispersable segment is estimated to be valued at US$ 1.92 billion in 2022.
• North America is the leading regional market with 60.3% share in 2021.
• Consumption of oral thin films is expected to increase at CAGRs of 12.5% and 24.2%, respectively, in Latin America and the Middle East and Africa.

"Surging adoption of novel oral thin films among geriatric & pediatric population boosting market value," says a Fact.MR analyst.

Market Development

At the introductory stage, oral thin film manufacturers have their focus on product innovation and development. Strong investments in research and development to address the existing limitations of oral thin film s, such as limited drug load and load of water-insoluble drugs, have led to several product launches and approval requests in the market.

Leaders in the oral thin films market are majorly investing in technological innovation and strategic expansion. Securing license agreement to boost international sales is also a key challenge.

• In August 2020, ZIM Laboratories Ltd. signed a licensing agreement with Hypera Pharma Group to market vitamin D3 in a novel oral thin film.
• In March 2021, Aquestive Therapeutics Inc. demonstrated an extensive review of the science, clinical results, and development strategy of its PharmFilm® oral sublingual film for administering epinephrine. This product is touted to effectively treat allergic reactions, including anaphylaxis.

Industry Research Report

• By Product Type :

o Oromucosal
 Sublingual Film
 Buccal Film
o Orodispersable

• By Indication :

o Pain Management
o Neurological Disorders
o Nausea & Vomiting
o Opioid Dependence
o Others

• By Distribution Channel :

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• By Region :

o North America
o Latin America
o Europe
o East Asia
o South Asia & ASEAN
o Oceania
o MEA

The best and most advanced tools are used to gather, record, estimate, and analyse market data in this market research study. When it comes to market control or making a name for oneself as the newest entrant, the comprehensive market report's data can be quite crucial.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=5776?AS

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : sales@factmr.com

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines.

This release was published on openPR.